Jeremiah Lorentz's questions to Fulcrum Therapeutics Inc (FULC) leadership • Q4 2024
Question
Jeremiah Lorentz, on behalf of BofA Securities, asked about the key takeaways from the upcoming FSHD data presentation and whether Fulcrum would consider a follow-on program. He also inquired about the operating expense outlook for 2025.
Answer
CEO Alexander Sapir explained that while the losmapimod drug performed as expected in the FSHD trial, a high placebo response meant the study missed its endpoint, and Fulcrum will not pursue it further, instead focusing on hematology. CFO Alan Musso stated that restructuring is complete and guided for a 2025 cash burn of $55 million to $65 million.